Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress. Nyquist et al.

Published: 14-05-2020| Version 1 | DOI: 10.17632/48v6t9r3w6.1
Contributor:
Mick Nyquist

Description

These are the uncropped western blots used in figures 3 and 4

Files